Table 1 composes a summary of the trials carried out targeting ET-1 signalling (Table 1). There are currently two clinical trials ongoing, with the first targeting ETBR-positive tumours, which contribute to immunomodulatory therapy resistance by inhibiting T-cell extravasation and tumour infiltration [44]. This evidence concerns the gene EDN1 and neoplasm.